Cambridge Healthtech Institute's Second Annual Pharmacogenomics:
A New Script for Prescriptions
October 18-19, 2000
Wyndham Franklin Plaza
Philadelphia, Pennsylvania
(Not sure exactly where to post this)
Pharmacogenomics is providing a new and steadier hand for the doctor's prescription pad. Each week startling information comes to light about unique variations in an individual's genetic makeup and the resulting highly variable responses to drug metabolism, effectiveness, or toxicity. Attention is inevitably drawn to major cytochrome p45o's, but also to less well known loci. Clinical results are nearing the expected critical mass whereby everyone must indeed "wake up and get ready for pharmacogenomics." At a recent Yale pharmacogenomics conference an industry leader prophesied that before the year was out he expected a major pharmaceutical company to be sued for selling a drug, old or new, without proper gene expression monitoring results. This seems a realistic threat. On an optimistic note, it is easy enough to see the day when pharmacogenomics can be regularly employed as a means to forestall or commute some predestined disease or condition, hereby improving living conditions universally.
DRUG TARGETS
Pharmacogenomics of CFTR and a CF Drug CPX in CF Cells
Dr. Harvey Pollard, Uniformed Services University School of Medicine
Drug Design Based upon Genetic Variation of Glutathione Metabolism
Dr. Ken Tew, Fox Chase Cancer Center
High-Density Biallelic Markers of the Human Genome for Identifying Genes Associated with Drug Response
Dr. François Thomas, GENSET S.A.
Title to Be Announced
Dr. Jason Simon, Schering-Plough Corporation (tentative)
METABOLISM/TOXICOLOGY
Application of P450, Genotyping to the Analysis of Kinetic Outliers
Dr. Tom Rushmore, Merck & Co., Inc. (tentative)
Database Analysis to Link Adverse Reactions to Drugs with Genetic Profiles
Dr. Ken Conway, Millennium Pharmaceuticals, Inc.
GeneCallingTM: A Comprehensive Differential mRNA Expression Technology Effective in Generating Drug-Induced Cardio- and Hepatotoxicity Profiles
Dr. Kellye Daniels, CuraGen Corporation
Pharmacogenomics: Identifying Tumor Promoters by Transcription Profiling
Dr. Marie-Charlotte von Brevern, BASF-LYNX Bioscience AG
Monitoring RNA Splicing Alterations for Predicting Drug Toxicity and Efficacy
Dr. Laurent Bracco, Exonhit Theraputics
CLINICAL APPLICATIONS
Where Does Clinical Pharmacology Meet Pharmacogenetics in Clinical Trial Analysis?
Dr. Roy Bullingham, Pharmacia, Inc. (tentative)
Application of Pharmacogenomics in Clinical Trials, Phases I-IV
Dr. Ronald Norton, PPGx, Inc.
Integating Clinical Data into Genome Analysis
Dr. Michael Liebman, Roche Bioscience
Variability in UGT1A1 Genotype to the Toxicity and Pharmacokinetics of Irinotecan
Dr. Lalitha Lyer, University of Chicago
COMMERCIAL IMPLICATIONS
Pharmacogenomic Strategies for Drug Marketing
Dr. Craig Fitzgerald, Glaxo Wellcome, plc (tentative)
How Will Pharmacogenomics Claims Be Translated into Clinical Findings, Drug Labeling, and Market Advantage?
Dr. William Wardell, Covance, Inc.
Maximizing the Economic Impact of Pharmacogenomics
Dr. Trevor Nicholls, Oxagen Limited
Title to Be Announced
Mr. Franklin Berger, JP Morgan Securities Inc.
TRAVEL INFORMATION
Special Airline Discounts Available
Special zone and discount fares have been established for this conference. Pleasae call Great International and National Travel at 617-527-0800 and ask for Joyce Dunn or e-mail her at jdunn@greatinrltravel.com. Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. Please fill out the registration form, with the poster title and primary author. To ensure inclusion in the conference binder, a one-page summary must be submitted and registration must be paid in full by September 15, 2000.
CALL FOR POSTERS
Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. Please fill out the registration form, with the poster title and primary author. To ensure inclusion in the conference binder, a one-page summary must be submitted and registration must be paid in full by September 15, 2000. POSTER INSTRUCTIONS
CALL FOR EXHIBITORS
Exhibit space is available for organizations interested in gaining exposure for their technology or services by reaching the targeted audience attending this conference. Please contact Jim MacNeil of Cambridge Healthtech Institute at 617-630-1341 to obtain an exhibitor package or to inquire about offering a workshop during the meeting. Exhibit space is limited so call now to reserve a space at this premier
event.
HOTEL INFORMATION
Wyndham Franklin Plaza Hotel
17th and Race Streets
Philadelphia, PA 19103
T: 215-448-2000
F: 215-448-2864
Room Rates: $155/Single o $165/Double
Cut-off Date: September 25, 2000
Please call the hotel directly to make your room reservation. Identify yourself as a Cambridge Healthtech
Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.
Cambridge Healthtech Institute
1037 Chestnut Street, Newton Upper Falls, MA 02164
Tel: 617-630-1300 • Fax: 617-630-1325
E-Mail: chi@healthtech.com |
